PHILADELPHIA—Immunotherapy has been lauded as a game changer for cancer patients, but these therapies can result in toxicities. As use of these treatments continues to grow, oncologists and gastroenterologists are likely to see more gastrointestinal, hepatic and pancreatic complications in patients undergoing adjuvant and neoadjuvant cancer therapies.
“As gastroenterologists and hepatologists, it’s essential that we identify and evaluate patients with suspected immune-related